Authors
Loading...
Randomized trial investigates enhanced antiviral efficacy of engineered nanobodies, suggesting a novel therapeutic approach.
Zhuchkov et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: